Orthocell Limited (OCC.AX) Stock Price, News & Chart

Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close0.5250

Open0.5300

Day range0.50000.5500

52-week range0.50001.3000

Off day high−6.36%

Off 52-week high−60.38%

Volume1.12M

Avg. volume (3M)340.83K

Market cap140.28M

EPS (TTM)-0.0500

Forward P/E-21.91

P/E ratio (TTM)—

Dividend yield—

Beta (5Y)—

Shares outstanding272.39M

Short interest—

Earnings dateAug 28, 2025 (est.)

Analyst target—

Profit margin—

Against its peers

Compare in full ›

	OCC.AX	CNXU	LCTX	CLGN	VCEL	MESO
Market cap	140.28M	95.58M	252.91M	6.94M	2.18B	1.59B
P/E (TTM)	—	—	—	—	90.5	—
Forward P/E	-21.9	-5.8	-7.3	-9.4	50.3	27.0
Price/book	4.1	14.5	4.1	1.8	5.9	2.8
Dividend yield	—	—	—	—	—	—
1-year change	−58.96%	−74.75%	−41.76%	−84.12%	+18.31%	−25.34%
Today	−1.90%	−6.06%	+1.52%	+1.38%	−1.02%	−2.15%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.

Related companies

Compare ›

The businesses closest to OCC.AX's by what they do, from their descriptions, with the same industry weighted in.

Company	Mkt cap	Price	Today
Conexeu Sciences Inc.CNXU · Biotechnology	95.58M	3.1000	−6.06%
Lineage Cell Therapeutics, Inc.LCTX · Biotechnology	252.91M	1.0000	+1.52%
CollPlant Biotechnologies Ltd.CLGN · Biotechnology	6.94M	3.6700	+1.38%
Vericel CorporationVCEL · Biotechnology	2.18B	42.53	−1.02%
Mesoblast LimitedMESO · Biotechnology	1.59B	12.28	−2.15%
Humacyte, Inc.HUMA · Biotechnology	120.95M	0.4354	+5.40%
Celularity Inc.CELU · Biotechnology	31.73M	0.9777	−6.89%
MediWound Ltd.MDWD · Biotechnology	154.92M	12.00	−1.48%

From the 4Search instruments index: what each company does (its business description), its industry, size, headquarters and the markets it serves; and from a year of daily prices, which move together. Prices may be delayed up to 15 min.

Latest news

All OCC.AX news ›

Finance News Network·Oct 12

Daily Special: Orthocell, WA Gold, PainChek, Piche Resources, CurveBeam AI

Finance News Network by Finance News Network October 13, 2026 12:58 PM

Stockhead·Oct 12Positive

Orthocell nerve repair product Remplir shows promise in prostate cancer surgery

Orthocell’s Remplir is showing promise in protecting nerves in prostatectomy procedures. Pic: Getty Images Special Report: Orthocell has received encouraging early functional recovery outcomes from an initial five-patient case series…

BiotechDispatch·Oct 12Positive

Orthocell bets on prostate surgery as five patient pilot paves way for US push

Perth-based regenerative medicine company Orthocell says its nerve repair device could open a new market in prostate cancer surgery. The company told investors that Remplir, its collagen device already approved for peripheral nerve…

Proactiveinvestors NA·Oct 12Negative

Small Cap Watch: Orthocell reports promising prostate surgery recovery data as Pilbara Gold extends high-grade discovery

The S&P/ASX Small Ordinaries Index (ASX) edged lower in its latest session as investors weighed developments across the healthcare and resources sectors, including promising clinical results from Orthocell, further high-grade gold…

Pluang·Oct 12

Orthocell's Remplir shows promising results in prostate cancer surgery, targeting a $2B US market expansion.

Orthocell Ltd reported positive early clinical results for its Remplir nerve repair technology in prostate cancer surgery, with 80% of patients regaining urinary continence and 75% showing erectile function recovery. The initial…

From articles in the 4Search news index.

In the news

7mentions in 30 days

7with it in the headline

Mixedsentiment

Most coverage from

proactiveinvestors.com2
biotechdispatch.com.au1
finnewsnetwork.com.au1
pluang.com1
sharecafe.com.au1

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.